FGF receptor signaling at the crossroads of endocrine homeostasis and tumorigenesis.
Multiple endocrine neoplasia (MEN) syndromes represent familial disorders characterized by endocrine cell growth and hormone production dysregulation. For several decades, the fibroblast growth factor (FGF) system has been suspected of playing a unique function in MEN-type I (MEN I). However, specific elucidation of these actions has been hampered by the overwhelming redundancy of this complex system. The human FGF family is composed of 22 members organized into 6 groups based on phylogenetic relationships. Signaling is mediated through membrane-spanning tyrosine kinase receptors encoded by four independent genes, some of which generate multiple products via alternative splicing or transcription initiation. High-affinity interaction between an FGF and its cognate receptor induces receptor dimerization and activation. Many FGFs display high-affinity interactions with multiple FGFRs, while some activate unique receptors or receptor isoforms. Most FGFs have demonstrated mitogenic activity in a variety of systems; however, a growing number display predominantly metabolic actions. This review will examine the evidence that FGF/FGFRs play a role in sporadic endocrine neoplasia and the pathways in which these molecules may be selectively targeted for therapeutic purposes.
Ezzat
S
S
Department of Medicine, University of Toronto, Endocrine Oncology Site Group, Mount Sinai & Princess Margaret Hospitals, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada. sezzat@mtsinai.on.ca
Asa
S L
SL
D000818:Animals; D005346:Fibroblast Growth Factors / Q000378:metabolism*; D006801:Humans; D018761:Multiple Endocrine Neoplasia Type 1 / Q000503:physiopathology*; D017468:Receptors, Fibroblast Growth Factor / Q000378:metabolism*; D015398:Signal Transduction
D017468:Receptors, Fibroblast Growth Factor; D005346:Fibroblast Growth Factors